| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/17/2003 | WO2001076573A3 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| 04/17/2003 | WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 04/17/2003 | US20030073845 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 04/17/2003 | US20030073833 Antiinflammatory agents; anticoagulants |
| 04/17/2003 | US20030073820 Hemoglobin conjugate for use in the synthetic blood |
| 04/17/2003 | US20030073819 PGC-1, a novel brown fat PPARgamma coactivator |
| 04/17/2003 | US20030073732 Antiinflammatory agents |
| 04/17/2003 | US20030073727 Central nervous system disorders |
| 04/17/2003 | US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease |
| 04/17/2003 | US20030073704 Analgesics; antidiabetic agents; antiinflamamtory agents |
| 04/17/2003 | US20030073702 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 04/17/2003 | US20030073682 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 04/17/2003 | US20030073660 Anticancer agents; blood disorders |
| 04/17/2003 | US20030073627 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 04/17/2003 | US20030073167 DNA encoding SNORF36 receptors |
| 04/17/2003 | US20030073076 Analyzing modulators or treatments of fibroproliferative diseases; obtain sample, incubate with modulator, monitor marker expression, decreased expression indicate effective modulator |
| 04/17/2003 | US20030072824 Having anti-oxidant, gastric mucosa injury inhibiting, aldose reductase inhibiting, blood glucose level elevation inhibiting action, platelet agglutination accelerating action, alcohol absorption inhibition, anti-inflammation properties |
| 04/17/2003 | US20030072818 For inhibiting platelet aggregation, for prolonging bleeding time |
| 04/17/2003 | US20030072808 Immediate release eplerenone compositions |
| 04/17/2003 | US20030072797 Pharmaceutical compositions for oral administration |
| 04/17/2003 | US20030072783 Administering nitric oxide adduct to a damaged vascular surface, wherein damaged vascular surface is interior surface of a blood vessel in which damage to endothelium or subendothelium, narrowing or stenosis of vessel has occured |
| 04/17/2003 | US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 04/17/2003 | CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | CA2463198A1 Pyrrolidinone derivatives |
| 04/17/2003 | CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | CA2462876A1 Compositions for and methods of treating and preventing sirs/sepsis |
| 04/17/2003 | CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | CA2461429A1 Peptides and related compounds having thrombopoietic activity |
| 04/17/2003 | CA2461064A1 Inhibition of stat-1 |
| 04/17/2003 | CA2460476A1 Protein modification and maintenance molecules |
| 04/17/2003 | CA2458473A1 Pharmaceutical formulation |
| 04/16/2003 | EP1302476A1 Reduced fk228 and use thereof |
| 04/16/2003 | EP1302462A1 Sulfone derivatives, process for their production and use thereof |
| 04/16/2003 | EP1302201A1 Pharmaceutical composition improved in peroral absorbability |
| 04/16/2003 | EP1301598A2 Cell cycle proteins and mitosis-associated molecules |
| 04/16/2003 | EP1301595A2 G-protein coupled receptors |
| 04/16/2003 | EP1301535A2 G-protein coupled receptors |
| 04/16/2003 | EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies |
| 04/16/2003 | EP1301516A1 Modulators of protein tyrosine phosphatases (ptpases) |
| 04/16/2003 | EP1301507A2 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 04/16/2003 | EP1301506A1 Cyclic amino acid derivatives |
| 04/16/2003 | EP1301501A1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 04/16/2003 | EP1301500A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 04/16/2003 | EP1301474A2 Tyrosine derivatives as phosphatase inhibitors |
| 04/16/2003 | EP1301211A2 Multifunctional nanodevice platform |
| 04/16/2003 | EP1301207A2 Compositions for treating bacterial infections, containing an oxazolidinone compound, sulbactam and and ampicillin |
| 04/16/2003 | EP1301194A1 Essential oil combination and therapeutic uses thereof |
| 04/16/2003 | EP1301181A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 04/16/2003 | EP1200105A4 Modified factor viii |
| 04/16/2003 | EP1181017B1 Metalloprotease inhibitors |
| 04/16/2003 | EP1056449B1 20-hete antagonists and agonists |
| 04/16/2003 | EP0922045B1 Bicyclic pyrimidine derivatives and their use as anti-coagulants |
| 04/16/2003 | EP0773955B1 New thrombin inhibitors, their preparation and use |
| 04/16/2003 | EP0742796B1 Il-3 variant hematopoiesis fusion protein |
| 04/16/2003 | EP0642356B1 Antibodies to p-selectin and their uses |
| 04/16/2003 | CN1411446A Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 04/16/2003 | CN1410536A Human source aprotinin gene, protein of said gene code and its application |
| 04/16/2003 | CN1105723C Spirocyclic metalloprotease inhibitors |
| 04/16/2003 | CN1105574C Therapeutic uses of bactericidal/permeability increasing protein products |
| 04/15/2003 | US6548694 N-(4-carbamimidoyl-phenyl)-glycine derivatives |
| 04/15/2003 | US6548533 Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion |
| 04/15/2003 | US6548520 Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| 04/15/2003 | US6548517 Oxindole inhibitors of factor Xa |
| 04/15/2003 | US6548514 Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders |
| 04/15/2003 | US6548512 Nitrogen containing heteroaromatics as factor Xa inhibitors |
| 04/15/2003 | US6548503 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 04/15/2003 | US6548284 Membrane-bound metalloprotease and soluble secreted form thereof |
| 04/15/2003 | US6548262 Hemostasis system-related disorders treatment |
| 04/15/2003 | US6548049 Medicinal aerosol formulation |
| 04/15/2003 | CA2261099C Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an hmg-coa-reductase inhibitor |
| 04/15/2003 | CA2059979C Complex containing coagulation factor ix |
| 04/15/2003 | CA2051504C 1-phenyl-3-aryl-2-propyne-1-ones as calcium uptake inhibitors |
| 04/10/2003 | WO2003029437A2 Secreted proteins |
| 04/10/2003 | WO2003029433A2 Chimeric viral vectors for gene therapy |
| 04/10/2003 | WO2003029424A2 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | WO2003029423A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | WO2003029410A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 04/10/2003 | WO2003029295A1 Human tissue factor antibodies |
| 04/10/2003 | WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy |
| 04/10/2003 | WO2003029291A2 Pegylated and diglycosylated erythropoietin |
| 04/10/2003 | WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use |
| 04/10/2003 | WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators |
| 04/10/2003 | WO2003029245A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | WO2003029224A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | WO2003029216A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | WO2003028763A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 04/10/2003 | WO2003028759A1 Rsv gene expression vaccine |
| 04/10/2003 | WO2003028756A2 An in vivo animal model of chronic arterial occlusion and use of collagenase to facilitate guide wire crossing in chronic arterial occlusions |
| 04/10/2003 | WO2003028743A1 Storage-stable fibrinogen solutions |
| 04/10/2003 | WO2003028729A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | WO2003028654A2 Storage-stable human fibrinogen solutions |
| 04/10/2003 | WO2003014326A3 Isolation and mobilization of stem cells expressing vegfr-1 |
| 04/10/2003 | WO2003000178A3 Black soybean polysaccharides |
| 04/10/2003 | WO2002092064A3 Therapeutic method for inducing tolerance |
| 04/10/2003 | WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure |
| 04/10/2003 | WO2002059083A3 Novel compounds |
| 04/10/2003 | WO2002009678A3 Charged phospholipid compositions and methods for their use |
| 04/10/2003 | WO2002008396A3 Human proteases |
| 04/10/2003 | US20030069430 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects |